Targeting Resident Cardiac Fibroblast Subpopulations for Protection Against Fibrosis
针对常驻心脏成纤维细胞亚群以预防纤维化
基本信息
- 批准号:10363496
- 负责人:
- 金额:$ 59.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2025-12-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAffectAftercareAmericanAngiotensin IIAreaAutomobile DrivingCardiacCause of DeathCellsCellular AssayChromatinChromatin StructureCicatrixDataDevelopmentEnsureEnzyme InhibitionEpigenetic ProcessExhibitsExtracellular MatrixFibroblastsFibrosisFutureGene ExpressionGenesHDAC2 geneHeartHeart DiseasesHeart failureHistone DeacetylaseHypertensionIn VitroInbred SHR RatsInfusion proceduresKnockout MiceLaboratory FindingLeftLeft ventricular structureMediatingMemoryMethodologyMissionModificationMyofibroblastNational Heart, Lung, and Blood InstitutePatientsPeptidyl-Dipeptidase APhenotypePhysiologicalPhysiologyPlayPopulationPreventionProcessProductionProtein IsoformsProteinsPublic HealthRattusResearchResistanceRisk FactorsRoleSignal TransductionSmall Interfering RNATestingTissuesTranscriptTransposaseValidationVentricularWorkbaseblood pressure reductioncardiogenesischromatin remodelingcoronary fibrosisexperimental studyfascinatehypertensivein vivoinjuredinterdisciplinary approachosteopontinpressurepreventresponsesingle-cell RNA sequencingtargeted treatmenttooltreatment strategy
项目摘要
PROJECT SUMMARY/ABSTRACT
Hypertension stimulates cardiac fibroblast (CF) expansion, activation, and excess extracellular matrix (ECM)
production. Although there are no approved treatments for cardiac fibrosis, angiotensin converting enzyme
inhibition (ACEi) limits CF activation and ECM accumulation. Recent findings from the laboratory of the PI
demonstrate that resident CFs, once considered functionally homogeneous, consist of physiologically distinct
populations that differentiate to diverse phenotypes in response to pressure overload. The premise for this
application is based on these findings in which hypertensive rats were transiently treated with an ACEi prior to
single cell RNA sequencing on resident CFs. Pre-treatment with ACEi shifts CF subpopulations to generate
homeostatic CFs with a reduced capacity for fibrosis. This effect persists after treatment is stopped, indicating
memory is retained. The proposed studies will reveal the mechanisms by which CF subpopulations shift to
determine how to reprogram CFs to display a homeostatic, less fibrogenic phenotype. Following ACEi,
homeostatic CFs comprise the largest subpopulation of resident CFs and are the least fibrogenic. Trajectory
analysis revealed a gateway CF subpopulation that is the immediate precursor to activated CFs, and this
gateway cluster was the most depleted by ACEi. Gateway CFs were defined by high expression of Spp1,
encoding for the protein osteopontin, which induces several pro-fibrotic genes and represents a critical target
candidate to maintain the activated CF pool. ACEi altered expression of epigenetic genes, indicating changes
in chromatin structure may drive the persistent shift from gateway to homeostatic CF subpopulations. These
compelling preliminary results led to the central hypothesis: transient reduction in angiotensin II signaling alters
CF memory to protect against left ventricle (LV) fibrosis by fibroblast subpopulation-specific reprogramming of
chromatin structure to shift an osteopontin-producing gateway subpopulation toward a homeostatic
subpopulation with low fibrogenic capacity. To test the hypothesis, the following specific aims are proposed:
Aim 1) elucidate the degree to which reduction in angiotensin II signaling mediates the persistent shift in
resident CF physiology that protects from future fibrosis; Aim 2) determine the impact of chromatin structural
modification on shifting the gateway cluster toward the homeostatic cluster; and Aim 3) ascertain the degree to
which reduction in osteopontin mediates the shift to a less fibrogenic phenotype. In this application, the
research team uses a multidisciplinary approach employing in vivo and in vitro methodologies to test the
hypothesis. Successful completion of these experiments will determine whether reduction in angiotensin II
signaling mediates the expansion of a subset of homeostatic CFs that renders the LV resistant to fibrosis. It is
expected that the key drivers regulating the shift from a gateway to a homeostatic subpopulation of CFs will be
identified. Impact: These anticipated findings will have a positive impact in developing CF-targeted therapies for
the treatment and prevention of fibrotic remodeling that underlies heart disease.
项目概要/摘要
高血压刺激心脏成纤维细胞 (CF) 扩张、活化和过量细胞外基质 (ECM)
生产。尽管尚无批准的治疗心脏纤维化的方法,但血管紧张素转换酶
抑制 (ACEi) 限制 CF 激活和 ECM 积累。 PI 实验室的最新发现
证明驻留 CF,曾经被认为功能同质,由生理上不同的组成
因压力超载而分化成不同表型的群体。这样做的前提是
该应用基于这些发现,其中高血压大鼠在治疗前短暂接受 ACEi 治疗
对常驻 CF 进行单细胞 RNA 测序。 ACEi 预处理可改变 CF 亚群以产生
纤维化能力降低的稳态 CF。这种效应在治疗停止后仍然存在,表明
记忆被保留。拟议的研究将揭示 CF 亚群转变为的机制
确定如何重新编程 CF 以显示稳态、纤维化较少的表型。继 ACEi 之后,
稳态 CF 包含最大的常驻 CF 亚群,并且纤维化程度最低。弹道
分析揭示了一个网关 CF 亚群,它是激活 CF 的直接前体,并且这
网关集群是 ACEi 消耗最严重的。 Gateway CF 由 Spp1 的高表达定义,
编码骨桥蛋白蛋白,可诱导多种促纤维化基因,是一个关键靶标
维护激活的 CF 池的候选者。 ACEi 改变了表观遗传基因的表达,表明发生了变化
染色质结构中的改变可能会驱动从门户向稳态 CF 亚群的持续转变。这些
令人信服的初步结果得出了中心假设:血管紧张素 II 信号传导的短暂减少会改变
CF记忆通过成纤维细胞亚群特异性重编程来防止左心室(LV)纤维化
染色质结构将产生骨桥蛋白的网关亚群转向稳态
纤维形成能力低的亚群。为了检验该假设,提出以下具体目标:
目标 1) 阐明血管紧张素 II 信号传导的减少在多大程度上介导了
常驻 CF 生理学可预防未来纤维化;目标 2) 确定染色质结构的影响
将网关集群转向稳态集群的修改;目标 3) 确定程度
骨桥蛋白的减少介导向纤维形成较少的表型的转变。在此应用中,
研究小组采用多学科方法,采用体内和体外方法来测试
假设。成功完成这些实验将决定血管紧张素 II 是否减少
信号传导介导稳态 CF 子集的扩张,使左心室抵抗纤维化。这是
预计调节CF从门户向稳态亚群转变的关键驱动因素将是
确定。影响:这些预期的发现将对开发 CF 靶向疗法产生积极影响
治疗和预防心脏病的纤维化重塑。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Taben M. Hale其他文献
Taben M. Hale的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Taben M. Hale', 18)}}的其他基金
Targeting Resident Cardiac Fibroblast Subpopulations for Protection Against Fibrosis
针对常驻心脏成纤维细胞亚群以预防纤维化
- 批准号:
10544519 - 财政年份:2022
- 资助金额:
$ 59.95万 - 项目类别:
相似国自然基金
TiC-TiB2颗粒喷射成形原位合成及其对M2高速工具钢共晶碳化物形成与演化的影响
- 批准号:52361020
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
植被群落演替对河道水流结构和纵向离散特性影响机制研究
- 批准号:52309088
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
热带印度洋海表皮温日变化的数值模拟及对海气热通量的影响
- 批准号:42376002
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
协同遥感和气候模型的城市高温热浪时空特征及其对热暴露影响研究
- 批准号:42371397
- 批准年份:2023
- 资助金额:46 万元
- 项目类别:面上项目
相似海外基金
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection
甲氨蝶呤治疗基孔肯雅病毒引起的关节炎(三月):甲氨蝶呤与安慰剂治疗基孔肯雅病毒感染后慢性关节炎的随机对照试验
- 批准号:
10444183 - 财政年份:2022
- 资助金额:
$ 59.95万 - 项目类别:
Defining Pre-treatment Correlates of Patient GD2 CAR T Cell Exhaustion and Memory Using Multi-Dimensional Immune Profiling
使用多维免疫分析定义患者 GD2 CAR T 细胞耗竭和记忆的预处理相关性
- 批准号:
10351423 - 财政年份:2022
- 资助金额:
$ 59.95万 - 项目类别:
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection
甲氨蝶呤治疗基孔肯雅病毒引起的关节炎(三月):甲氨蝶呤与安慰剂治疗基孔肯雅病毒感染后慢性关节炎的随机对照试验
- 批准号:
10693136 - 财政年份:2022
- 资助金额:
$ 59.95万 - 项目类别:
Defining Pre-treatment Correlates of Patient GD2 CAR T Cell Exhaustion and Memory Using Multi-Dimensional Immune Profiling
使用多维免疫分析定义患者 GD2 CAR T 细胞耗竭和记忆的预处理相关性
- 批准号:
10606473 - 财政年份:2022
- 资助金额:
$ 59.95万 - 项目类别:
New Epigenetic Targets in Ovarian Cancer Stem Cells
卵巢癌干细胞的新表观遗传靶点
- 批准号:
9888658 - 财政年份:2010
- 资助金额:
$ 59.95万 - 项目类别: